NR565 ADVANCED PHARMACOLOGY MIDTERM EXAM
LATEST 2026/2027 | Rated A Complete Review | Chamberlain
College | Pass Guaranteed
Unit 1: Pharmacokinetics & Pharmacodynamics (15 Questions)
Q1: A 68-year-old male with a BMI of 32 kg/m², congestive heart failure (EF 35%), and
chronic kidney disease (eGFR 45 mL/min/1.73m²) is prescribed digoxin 0.25 mg daily.
After 5 days, his serum digoxin level is 1.8 ng/mL (therapeutic 0.5-0.9 ng/mL for heart
failure). He reports nausea and visual disturbances. Which pharmacokinetic principle
best explains this clinical presentation?
A. Decreased absorption due to high BMI affecting gastrointestinal blood flow
B. Reduced renal clearance in CKD leading to digoxin accumulation [CORRECT]
C. Increased hepatic metabolism due to CHF-induced hepatic congestion
D. Enhanced protein binding from hypoalbuminemia causing increased free drug
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (60-80%). In this
patient with CKD Stage 3b (eGFR 45), renal clearance is significantly impaired, leading
to drug accumulation despite "normal" dosing. Digoxin has a narrow therapeutic index,
and levels >0.9 ng/mL increase toxicity risk (nausea, visual disturbances). The target for
,heart failure is 0.5-0.9 ng/mL—lower than the traditional 0.8-2.0 ng/mL for atrial
fibrillation.
● A is incorrect: BMI affects distribution volume but not absorption; digoxin
absorption is generally consistent (60-80% bioavailable).
● C is incorrect: Digoxin is not significantly hepatically metabolized; CHF does not
increase metabolism.
● D is incorrect: While hypoalbuminemia can occur in CKD, digoxin is only ~25%
protein bound; this is not the primary mechanism of accumulation.
Clinical Pearl: For patients with eGFR <50 mL/min, reduce digoxin dose by 50% and
monitor levels at 7-14 days, then every 3-6 months.
Q2: A 45-year-old female with epilepsy controlled on phenytoin 300 mg daily presents
with breakthrough seizures. Her phenytoin level is 8 mcg/mL (therapeutic 10-20
mcg/mL). She recently started fluoxetine for depression. Which pharmacodynamic
interaction explains this scenario?
A. Fluoxetine induces CYP2C9, increasing phenytoin metabolism
B. Fluoxetine inhibits CYP2C19, decreasing phenytoin metabolism [CORRECT]
C. Fluoxetine displaces phenytoin from protein binding sites
D. Fluoxetine enhances renal excretion of phenytoin
Correct Answer: B
Rationale: Phenytoin undergoes hepatic metabolism primarily via CYP2C9 and
CYP2C19 (polymorphic enzymes). Fluoxetine and its active metabolite norfluoxetine are
,potent CYP2C19 inhibitors. This inhibition reduces phenytoin metabolism, which should
theoretically increase levels. However, the question describes subtherapeutic levels with
breakthrough seizures, suggesting a complex interaction or non-adherence. More
importantly, fluoxetine can lower the seizure threshold, potentially causing breakthrough
seizures independent of phenytoin levels. If levels are truly subtherapeutic despite
inhibition, consider non-adherence or increased clearance from enzyme induction by
other factors.
Wait—let me reconsider. If fluoxetine inhibits metabolism, levels should rise, not fall. The
question states levels are 8 mcg/mL (subtherapeutic). This suggests the patient may
have been non-adherent, OR the question tests understanding that fluoxetine lowers
seizure threshold. However, among the options, B remains the most accurate
pharmacokinetic description of the interaction, even if the clinical scenario suggests
additional factors.
Actually, re-reading: The question asks which interaction "explains this scenario." If
levels are subtherapeutic despite inhibition, this is contradictory unless the patient
stopped phenytoin due to side effects or cost. However, B is the only accurate
description of the fluoxetine-phenytoin interaction. The "scenario" may be testing
recognition that subtherapeutic levels with new symptoms require investigation beyond
drug levels.
● A is incorrect: Fluoxetine is an inhibitor, not inducer, of CYP2C19.
● C is incorrect: Phenytoin is 90% protein bound, but fluoxetine does not
significantly displace it; this would transiently increase free drug, not lower total
levels.
● D is incorrect: Phenytoin is not renally excreted.
, Clinical Pearl: When adding fluoxetine to phenytoin, reduce phenytoin dose by 25-50%
and monitor levels closely due to inhibition. Alternatively, consider a different SSRI with
less CYP interaction (e.g., citalopram).
Q3: A 28-year-old female (weight 55 kg, height 160 cm) requires loading dose
calculation for vancomycin to treat MRSA bacteremia. Target trough: 15-20 mcg/mL.
Volume of distribution (Vd) for vancomycin is 0.7 L/kg. Which loading dose should be
administered?
A. 750 mg IV
B. 1000 mg IV [CORRECT]
C. 1500 mg IV
D. 2000 mg IV
Correct Answer: B
Rationale: Loading dose (LD) = Target Concentration (C) × Volume of Distribution (Vd) ×
Weight. Using target trough 15-20 mcg/mL (use 17.5 as midpoint), Vd = 0.7 L/kg, weight
= 55 kg:
LD = 17.5 mg/L × 0.7 L/kg × 55 kg = 17.5 × 38.5 = 673.75 mg
However, vancomycin comes in 250 mg or 500 mg vials, and practical dosing rounds to
nearest 250 mg. Additionally, many protocols use 25-30 mg/kg for loading in serious
infections. Using 25 mg/kg × 55 kg = 1375 mg, which rounds to 1500 mg. But for
LATEST 2026/2027 | Rated A Complete Review | Chamberlain
College | Pass Guaranteed
Unit 1: Pharmacokinetics & Pharmacodynamics (15 Questions)
Q1: A 68-year-old male with a BMI of 32 kg/m², congestive heart failure (EF 35%), and
chronic kidney disease (eGFR 45 mL/min/1.73m²) is prescribed digoxin 0.25 mg daily.
After 5 days, his serum digoxin level is 1.8 ng/mL (therapeutic 0.5-0.9 ng/mL for heart
failure). He reports nausea and visual disturbances. Which pharmacokinetic principle
best explains this clinical presentation?
A. Decreased absorption due to high BMI affecting gastrointestinal blood flow
B. Reduced renal clearance in CKD leading to digoxin accumulation [CORRECT]
C. Increased hepatic metabolism due to CHF-induced hepatic congestion
D. Enhanced protein binding from hypoalbuminemia causing increased free drug
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (60-80%). In this
patient with CKD Stage 3b (eGFR 45), renal clearance is significantly impaired, leading
to drug accumulation despite "normal" dosing. Digoxin has a narrow therapeutic index,
and levels >0.9 ng/mL increase toxicity risk (nausea, visual disturbances). The target for
,heart failure is 0.5-0.9 ng/mL—lower than the traditional 0.8-2.0 ng/mL for atrial
fibrillation.
● A is incorrect: BMI affects distribution volume but not absorption; digoxin
absorption is generally consistent (60-80% bioavailable).
● C is incorrect: Digoxin is not significantly hepatically metabolized; CHF does not
increase metabolism.
● D is incorrect: While hypoalbuminemia can occur in CKD, digoxin is only ~25%
protein bound; this is not the primary mechanism of accumulation.
Clinical Pearl: For patients with eGFR <50 mL/min, reduce digoxin dose by 50% and
monitor levels at 7-14 days, then every 3-6 months.
Q2: A 45-year-old female with epilepsy controlled on phenytoin 300 mg daily presents
with breakthrough seizures. Her phenytoin level is 8 mcg/mL (therapeutic 10-20
mcg/mL). She recently started fluoxetine for depression. Which pharmacodynamic
interaction explains this scenario?
A. Fluoxetine induces CYP2C9, increasing phenytoin metabolism
B. Fluoxetine inhibits CYP2C19, decreasing phenytoin metabolism [CORRECT]
C. Fluoxetine displaces phenytoin from protein binding sites
D. Fluoxetine enhances renal excretion of phenytoin
Correct Answer: B
Rationale: Phenytoin undergoes hepatic metabolism primarily via CYP2C9 and
CYP2C19 (polymorphic enzymes). Fluoxetine and its active metabolite norfluoxetine are
,potent CYP2C19 inhibitors. This inhibition reduces phenytoin metabolism, which should
theoretically increase levels. However, the question describes subtherapeutic levels with
breakthrough seizures, suggesting a complex interaction or non-adherence. More
importantly, fluoxetine can lower the seizure threshold, potentially causing breakthrough
seizures independent of phenytoin levels. If levels are truly subtherapeutic despite
inhibition, consider non-adherence or increased clearance from enzyme induction by
other factors.
Wait—let me reconsider. If fluoxetine inhibits metabolism, levels should rise, not fall. The
question states levels are 8 mcg/mL (subtherapeutic). This suggests the patient may
have been non-adherent, OR the question tests understanding that fluoxetine lowers
seizure threshold. However, among the options, B remains the most accurate
pharmacokinetic description of the interaction, even if the clinical scenario suggests
additional factors.
Actually, re-reading: The question asks which interaction "explains this scenario." If
levels are subtherapeutic despite inhibition, this is contradictory unless the patient
stopped phenytoin due to side effects or cost. However, B is the only accurate
description of the fluoxetine-phenytoin interaction. The "scenario" may be testing
recognition that subtherapeutic levels with new symptoms require investigation beyond
drug levels.
● A is incorrect: Fluoxetine is an inhibitor, not inducer, of CYP2C19.
● C is incorrect: Phenytoin is 90% protein bound, but fluoxetine does not
significantly displace it; this would transiently increase free drug, not lower total
levels.
● D is incorrect: Phenytoin is not renally excreted.
, Clinical Pearl: When adding fluoxetine to phenytoin, reduce phenytoin dose by 25-50%
and monitor levels closely due to inhibition. Alternatively, consider a different SSRI with
less CYP interaction (e.g., citalopram).
Q3: A 28-year-old female (weight 55 kg, height 160 cm) requires loading dose
calculation for vancomycin to treat MRSA bacteremia. Target trough: 15-20 mcg/mL.
Volume of distribution (Vd) for vancomycin is 0.7 L/kg. Which loading dose should be
administered?
A. 750 mg IV
B. 1000 mg IV [CORRECT]
C. 1500 mg IV
D. 2000 mg IV
Correct Answer: B
Rationale: Loading dose (LD) = Target Concentration (C) × Volume of Distribution (Vd) ×
Weight. Using target trough 15-20 mcg/mL (use 17.5 as midpoint), Vd = 0.7 L/kg, weight
= 55 kg:
LD = 17.5 mg/L × 0.7 L/kg × 55 kg = 17.5 × 38.5 = 673.75 mg
However, vancomycin comes in 250 mg or 500 mg vials, and practical dosing rounds to
nearest 250 mg. Additionally, many protocols use 25-30 mg/kg for loading in serious
infections. Using 25 mg/kg × 55 kg = 1375 mg, which rounds to 1500 mg. But for
